Walmsley Looks Safe For Now, But GSK Faces M&A Pressure
Strategy Debate Will Rumble On
Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.
You may also be interested in...
GSK Unveils Plans For Major Europe Biotech Cluster
The under-pressure drugs giant has something to cheer with plans for a new campus that could attract several world-class research organizations to its doorstep and bring a multi-million pound windfall from the sale of land.
GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.